1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid (abbreviated as TMTCA) is a **tricyclic organic compound** that contains a cyclohexane ring with three methyl groups and three carboxylic acid groups attached to the ring.
**Importance in Research:**
While not a widely known compound like some others, TMTCA is significant in research because:
* **Potential pharmaceutical applications:**
* Its structure resembles certain **natural products** that exhibit biological activity, including **anticancer** and **anti-inflammatory** properties. Researchers are exploring its potential as a lead compound for developing new drugs.
* The presence of multiple carboxylic acid groups makes it a potential candidate for **drug delivery systems** due to its ability to form salts and complexes.
* **Study of molecular recognition:**
* The rigid, multi-functional structure of TMTCA makes it a useful model compound for studying **host-guest interactions** and **molecular recognition** principles. These studies can be valuable in understanding and designing new sensors, catalysts, and other functional materials.
* **Synthesis and materials science:**
* TMTCA's unique structure presents challenges and opportunities for **organic synthesis**. It can be used as a building block for constructing complex molecules and supramolecular assemblies with specific properties.
* Its presence in **polymers** and **plastics** is being investigated for potential applications in materials science.
**Overall, TMTCA is a promising molecule for research due to its potential applications in pharmaceuticals, molecular recognition, and materials science. Further investigation and development are needed to unlock its full potential.**
**Please note:** The information provided here is based on general research trends and the compound's structural properties. Specific applications and current research progress may vary. It's essential to consult specialized literature and databases for the most up-to-date information.
1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 688137 |
| CHEMBL ID | 1588081 |
| SCHEMBL ID | 405480 |
| SCHEMBL ID | 503244 |
| SCHEMBL ID | 13490845 |
| MeSH ID | M0421278 |
| Synonym |
|---|
| HMS1590P20 |
| AKOS002720730 |
| OPREA1_038050 |
| 1,3,5-trimethyl-1,3,5-cyclohexanetricarboxylic acid |
| MLS000096767 , |
| smr000074082 |
| cis,cis-1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid, 99% |
| cis,cis-1,3,5-trimethyl-1,3,5-cyclohexanetricarboxylic acid |
| 79410-20-1 |
| 1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid |
| AKOS002272589 |
| 118514-35-5 |
| HMS2153A13 |
| cis,cis-1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid |
| HMS3314K03 |
| mfcd01545994 |
| SCHEMBL405480 |
| SCHEMBL503244 |
| CHEMBL1588081 |
| kemp's triacid |
| SCHEMBL13490845 |
| cid_688137 |
| bdbm59720 |
| 136662-41-4 |
| kemps triacid |
| (1s,3s,5s)-1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid |
| STL512757 |
| Q11751620 |
| kemp's acid |
| 1,3,5-trimethylcyclohexane-1,3,5-tricarboxylicacid |
| (1r,3s,5s)-1,3,5-trimethylcyclohexane-1,3,5-tricarboxylic acid |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Smad3 | Homo sapiens (human) | Potency | 15.8489 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 (µMol) | 58.6900 | 1.0000 | 27.8360 | 138.0800 | AID1619 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||